Cure-IO for pharma and biotech

Find the patients your therapy was built for.

Use explainable response and toxicity models across ICIs, ADCs, bispecifics and CAR-T to design smarter trials, read real-world data faster and shape your launch strategy.

Licensing options
Two scientists working at computers in a laboratory
Live Responder enrichment, scored in under a second
4therapy-class models under one licence
Phase I–IVuse across the development cycle
VPC / on-premyour data stays in your environment
21 CFR Part 11audit-ready logging for GxP studies
Use cases

Where Cure-IO fits in your pipeline.

Trial enrichment

Score screened patients for likely response and toxicity to build enriched or stratified cohorts, and model the effect on sample size before you commit.

Safety forecasting

Anticipate irAEs, ILD with ADCs, and CRS or ICANS with bispecifics and CAR-T. Plan monitoring intensity by predicted risk.

Real-world evidence

Run the models across RWD cohorts to compare expected and observed response, find under-served subgroups and support HTA submissions.

Combination strategy

Compare predicted benefit and risk across regimens to prioritise combination arms and sequencing.

Co-development

Fine-tune a dedicated model on your trial data under a joint development agreement, with the IP terms agreed up front.

Launch and access

Equip medical affairs with an explainable tool that helps treating centres identify appropriate patients after approval.

Engagement path

From pilot to programme in four stages.

Weeks 0–2Scoping

Indication, endpoints and data sources agreed. DPA signed.

Weeks 2–6Retrospective fit

Models run on your historical trial or RWD data.

Weeks 6–8Readout

Calibration, subgroup performance and enrichment simulations.

Month 3+Deploy

API or on-prem install for live screening.

OngoingMonitor

Drift tracking and quarterly model reviews.

Model coverage

What each model predicts.

ModelEfficacy outputsSafety outputsStatus
Immunotherapy (ICI)Objective response, 12-month PFS, OS hazardGrade ≥3 irAE, organ-specific irAE (colitis, pneumonitis, hepatitis)Available
Antibody–drug conjugatesObjective response, time on treatmentILD / pneumonitis, neutropenia, ocular toxicityEarly access
Bispecific antibodiesResponse, early progressionCytokine release syndrome grade, ICANSEarly access
CAR-T cell therapyComplete response, durability at 12 monthsCRS, ICANS, prolonged cytopeniaIn development

Ready to get started?

Book a demo, or start free in the Sandbox.

See how Cure-IO fits your clinic, your trial or your product. We’ll walk your clinical, data or pharma team through the models in 30 minutes.

Cure-IO FAQs

Questions?

Regulation, licensing, data handling and how each model works.

Read the FAQs

Get Cure-IO updates